0512-67998889(Suzhou)
18051093220(Shenzhen)
|
Pipeline Code
|
Adaptability
|
Target
|
Technology Platform
|
Proof of Concept
|
Animal Experiment
|
IIT
|
IND
|
Comparison
|
|
RR-M01
|
Ovarian cancer
|
HER2
|
24H
|
   RocRock Affiliated Hospital of Xuzhou Medical University |
First in class
|
|||
|
RR-M01*
|
Stomach pancreatic breast cancer
|
HER2
|
24H
|
  RocRock Affiliated Hospital of Xuzhou Medical University |
First in class
|
|||
|
RR-M02
|
Pancreatic cancer
|
***
|
24H
|
  RocRock Peking Union Medical College Hospital |
First in class
|
|||
|
RR-M03
|
Lung cancer
|
***
|
24H
|
|
First in class
|
|||
|
RR-M04
|
Prostate cancer
|
***
|
24H
|
|
First in class
|
|||
|
RR-M05
|
Liver cancer
|
***
|
24H
|
|
First in class
|
|||
|
RR-M06
|
Brain glioma
|
***
|
24H
|
  RocRock Wuhan Tongji Hospital |
First in class
|
|||
|
RR-M07
|
Systemic lupus erythematosus
|
***
|
24H
|
  RocRock Nanjing Gulou Hospital |
First in class
|
|||
|
RR-M08
|
Pulmonary fibrosis
|
***
|
24H
|
|
First in class
|
|||
|
RR-M09
|
Pulmonary fibrosis
|
***
|
24H
|
|
First in class
|
|||
0512-67998889(Suzhou)
18051093220(Shenzhen)
Cathy.Lv@rocrockbio.com(Suzhou)
lliangjing@rocrockbio.com (Shenzhen)